en · de · es · fr · pt
sr9009-notes.peptides9000.com › Data › Sr9009 Background And Receptor Mechanism — Explained

Sr9009 Background And Receptor Mechanism — Explained

By Editorial Desk · published 2026-03-29 · last reviewed 2026-04-16 · Data

freeze-thaw cycle raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.

This page was last updated on 2026-04-16 and is reviewed periodically as new material appears.

SR9009 Background and Receptor Mechanism

SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.

SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.

Analytical Detection and Storage

Storage recommendations for SR9009 reference material typically specify a freezer at -20 °C or lower, with protection from moisture and light. Repeated freeze-thaw cycles can degrade small molecules and introduce variability. Stock solutions in dimethyl sulfoxide are often aliquoted to avoid repeated handling. Stability studies may examine degradation under heat, humidity, and light exposure. The compound's thiophene and nitro groups can participate in reactions that alter analytical signals over time, so such changes affect quantitative results.

Quality control for research materials includes identity confirmation by nuclear magnetic resonance and purity assessment by high-performance liquid chromatography. Mass spectrometry provides molecular weight confirmation and can detect related impurities. Purchasers should request a certificate of analysis that lists lot-specific data. Online products advertised for human use often lack such documentation. Distinguishing legitimate research material from mislabeled or contaminated samples is a recurring challenge in independent testing, and independent laboratories may use orthogonal methods to verify identity.

Sr9009 at a glance

PropertyValueNotes
Chemical classSynthetic REV-ERB agonistSmall-molecule nuclear receptor ligand
AppearanceOff-white to pale yellow solidTypical for research-grade powder
Solubility classSoluble in DMSO; low water solubilityCommon stock solutions use organic solvent
Typical stock solventDimethyl sulfoxideUsed for laboratory assays
Common analytical methodHPLC with UV or mass detectionUsed for identity and purity checks

Background and Receptor Mechanism

Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.

SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.

At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.

Related pages on this site

Identity, Handling, and Regulation

Regulatory status varies by country and intended use. Major drug agencies have not granted marketing authorization for SR9009 as a medicine, and it is not listed as a controlled substance in many jurisdictions. It is often sold as a research chemical, a category that may fall outside pharmaceutical manufacturing rules. Buyers should verify local laws and supplier documentation, including certificates of analysis. The lack of standardized quality controls raises concerns about identity, purity, and actual content in products marketed online.

In laboratory settings, SR9009 is commonly identified by its molecular structure and its interaction with REV-ERB receptors. Vendors may list it under synonyms such as Stenabolic or REV-ERB agonist, but those names do not define purity or identity. Analytical confirmation typically uses high-performance liquid chromatography with ultraviolet detection or liquid chromatography–mass spectrometry. A reference standard is needed to compare retention time and mass spectrum, because the compound can be confused with related research chemicals.

Further detail

Pizza Hut sponsored the film Back to the Future Part II (1989) and offered a free pair of futuristic sunglasses, known as "Solar Shades", with the purchase of Pizza Hut pizza. Pizza Hut also engaged in product placement within the film, having a futuristic version of their logo with their trademarked red hut printed on the side of a mylar dehydrated pizza wrapper in the McFly family dinner scene, and appear on a storefront in Hill Valley in the year 2015. In 1990, Pizza Hut spent a reported $20 million to sponsor the Teenage Mutant Ninja Turtles Coming Out of Their Shells live musical. The company also gave out a Ninja Turtle audio cassette as part of a promotion. The 1990 NES game Teenage Mutant Ninja Turtles II: The Arcade Game came with a coupon for a free pizza. The game included Pizza Hut product placement in the form of background advertisements and pizza that would refill the character's life. In the early 1990s, Pizza Hut sought to attract children and pre-teenagers to build its dine-in business. Through comedy writer Walter Williams and San Francisco advertising agency Goodby, Silverstein & Partners, Pizza Hut created The Pizza Head Show, a series of television commercials to convey the message that Pizza Hut meant "weird fun". The commercials featured spokes-character Pizza Head and his pizza-cutter nemesis Steve, in a format reminiscent of Williams's previous production Mr. Bill. In 1995, Donald Trump and his first wife Ivana Trump appeared in a commercial.

An alternative model, proposed by politicians in Oldenburg and Brunswick, envisaged the foundation of the independent state of "Weser-Ems", that would be formed from the state of Oldenburg, the Hanseatic City of Bremen and the administrative regions of Aurich and Osnabrück. Several representatives of the state of Oldenburg even demanded the inclusion of the Hanoverian districts of Diepholz, Syke, Osterholz-Scharmbeck and Wesermünde in the proposed state of "Weser-Ems". Likewise an enlarged State of Brunswick was proposed in the southeast to include the Regierungsbezirk of Hildesheim and the district of Gifhorn. Had this plan come to fruition, the territory of the present Lower Saxony would have consisted of three states of roughly equal size. The district council of Vechta protested on 12 June 1946 against being incorporated into the metropolitan area of Hanover (Großraum Hannover). If the State of Oldenburg was to be dissolved, Vechta District would much rather be included in the Westphalian region. Particularly in the districts where there was a political Catholicism the notion was widespread, that Oldenburg Münsterland and the Regierungsbezirk of Osnabrück should be part of a newly formed State of Westphalia. Since the foundation of the states of North Rhine-Westphalia and Hanover on 23 August 1946 the northern and eastern border of North Rhine-Westphalia has largely been identical with that of the Prussian Province of Westphalia. Only the Free State of Lippe was not incorporated into North Rhine-Westphalia until January 1947.

K a = [ H + ] [ A − ] [ HA ] {\displaystyle K_{a}={\frac {{\ce {[H+] [A^{-}]}}}{{\ce {[HA]}}}}} The stronger of two acids will have a higher Ka than the weaker acid; the ratio of hydrogen cations to acid will be higher for the stronger acid as the stronger acid has a greater tendency to lose its proton. Because the range of possible values for Ka spans many orders of magnitude, a more manageable constant, pKa is more frequently used, where pKa = −log10 Ka. Stronger acids have a smaller pKa than weaker acids. Experimentally determined pKa at 25 °C in aqueous solution are often quoted in textbooks and reference material. Arrhenius acids are named according to their anions. In the classical naming system, the ionic suffix is dropped and replaced with a new suffix, according to the table following. The prefix "hydro-" is used when the acid is made up of just hydrogen and one other element. For example, HCl has chloride as its anion, so the hydro- prefix is used, and the -ide suffix makes the name take the form hydrochloric acid. Classical naming system:

Both agonist and antagonist bond the same active site. Adding agonist dose can reverse the effect of reversible competitive antagonism. Irreversible competitive antagonism occurs when the antagonist binds to the same spot on the receptor as the agonist but dissociates from the receptors very slowly or not. As a result, when the agonist is delivered, there is no change in the antagonist occupancy. Since a receptor can only hold one molecule at a time, competitive antagonists can reduce the agonist occupancy (percentage of receptors to which the agonist is bound). Raising the agonist concentration can bring back the agonist occupancy and the subsequent tissue response due to their competition. Thus, the opposition is surmountable. The amount to which the competitive antagonist causes the agonist log concentration–effect curve to shift to the right while maintaining its maximum slope is a measure of the dosage ratio. The antagonist concentration causes the dosage ratio to rise linearly.

Sources: en.wikipedia.org

Supporting material

Primary hypolactasia Primary hypolactasia, or primary lactase deficiency, is genetic, develops in childhood at various ages, and is caused by the absence of a lactase persistence allele. In individuals without the lactase persistence allele, less lactase is produced by the body over time, leading to hypolactasia in adulthood. The frequency of lactase persistence, which allows lactose tolerance, varies enormously worldwide, with the highest prevalence in Northwestern Europe, declines across southern Europe and the Middle East and is low in Asia and most of Africa, although it is common in pastoralist populations from Africa. Secondary hypolactasia Secondary hypolactasia or secondary lactase deficiency, also called acquired hypolactasia or acquired lactase deficiency, is caused by an injury to the small intestine. This form of lactose intolerance can occur in both infants and lactase persistent adults and is generally reversible. It may be caused by acute gastroenteritis, celiac disease, Crohn's disease, ulcerative colitis, chemotherapy, intestinal parasites (such as giardia), or other environmental causes. Primary congenital alactasia Primary congenital alactasia, also called congenital lactase deficiency, is an extremely rare, autosomal recessive enzyme defect that prevents lactase expression from birth. People with congenital lactase deficiency cannot digest lactose from birth, so cannot digest breast milk. This genetic defect is characterized by a complete lack of lactase (alactasia). About 40 cases have been reported worldwide, mainly limited to Finland.

=== Mixed fortunes in the 21st century === The team were relegated to the Second Division in 2002; administration threatened the existence of the club as Barnsley suffered greatly due to the ITV Digital crisis. A late purchase by Barnsley's then mayor, Peter Doyle, saved the club from folding. In 2006, the side won in the play-off final at the Millennium Stadium in Cardiff, where they beat Swansea City 4–3 on penalties to earn promotion to the Championship. The manager at this time was Andy Ritchie, who was in his first season in charge after replacing Paul Hart. The team struggled in their first season back in the Championship. In November 2006, with Barnsley in the relegation zone, Ritchie was sacked in favour of Simon Davey, who managed to steer the team away from relegation in the second half of the season, and they eventually finished 20th. The following season, Barnsley reached the semi-final of the FA Cup, beating Premier League side Liverpool 2–1 at Anfield and defending champions Chelsea 1–0; the team lost 1–0 against fellow Championship side Cardiff City at Wembley in the semi-final. In October 2008, the club fielded the youngest player in the Football League's history when Reuben Noble-Lazarus came on against Ipswich Town aged 15 years and 45 days. Barnsley ended the 2011–12 season as one of only two football clubs to turn a profit in the Championship; they stayed up only because Portsmouth were given a 10-point deduction for going into administration. In 2016, Barnsley won the Football League Trophy after a 3–2 win against Oxford United.

Pictures, movies and applets showing the anatomy of Mus musculus, from www.digimorph.org Michael Purdy: "Researchers add mice to list of creatures that sing in the presence of mates" Archived 2008-12-26 at the Wayback Machine-Study of male mouse "song" with mouse song recording (MP3), by Washington University Medical School "It's just in mice! This scientist is calling out hype in science reporting". STAT. 2019-04-15. Arkive Photographs.Short text. High-Resolution Brain Maps and Brain Atlases of Mus musculus Further reading

In a ranking of cities by safety that was prepared by The Economist newspaper in 2021, Moscow was ranked 38th with a score of 62.5 points. The general level of crime is low. More than 170,000 surveillance cameras in Moscow are connected to a facial recognition system. The authorities approved of a two-month experiment with automatic, real-time recognition of faces, gender, and age of people; so these authorities deployed the system around the entire city. A video surveillance network integrates video cameras in 95% of the city's apartment buildings; on the grounds and inside buildings of schools and kindergartens; and in MCC stations, stadiums, public transit stops, bus stations, parks, and underground passages. Moscow's emergency numbers match those in all other regions of Russia:

== Structure == This gene encodes a member of the glutathione peroxidase family, consisting of eight known glutathione peroxidases (GPx1-8) in humans. Mammalian Gpx1 (this gene), Gpx2, Gpx3, and Gpx4 have been shown to be selenium-containing enzymes, whereas Gpx6 is a selenoprotein in humans with cysteine-containing homologues in rodents. In selenoproteins, the 21st amino acid selenocysteine is inserted in the nascent polypeptide chain during the process of translational recoding of the UGA stop codon. In addition to the UGA-codon, a cis-acting element in the mRNA, called SECIS, binds SBP2 to recruit other proteins, such as eukaryotic elongation factor selenocysteine-tRNA specific, to form the complex responsible for the recoding process. The protein encoded by this gene forms a homotetramer structure. As with other glutathione peroxidases, GPx1 has a conserved catalytic tetrad composed of Sec or Cys, Gln, Trp, and Asn, where the Sec is surrounded by four arginines (R 57, 103, 184, 185; bovine numbering) and a lysine of an adjacent subunit (K 91'). These 5 residues bind glutathione (GSH) and are only present in GPx1. Two alternatively spliced transcript variants encoding distinct isoforms have been found for this gene. Glutathione peroxidase 1 is characterized in a polyalanine sequence polymorphism in the N-terminal region, which includes three alleles with five, six or seven alanine (Ala) repeats in this sequence. The allele with five Ala repeats is significantly associated with breast cancer risk.

Sources: en.wikipedia.org

Frequently asked questions

What is SR9009?

SR9009 is a synthetic research compound that acts on REV-ERB nuclear receptors. It is not approved for human use and is sold only as a research chemical. Its effects have been studied mainly in cells and rodents.

How does SR9009 work?

It binds REV-ERB alpha and REV-ERB beta and changes the expression of genes tied to metabolism and circadian rhythm. These changes can affect mitochondria and energy use in animal models. The exact chain from receptor binding to physiological outcome is still being mapped.

Is SR9009 a proven performance enhancer?

No reliable human trials show that SR9009 improves athletic performance. Some rodent studies report endurance changes, but these results are not proof of human benefit. Its use in sport is prohibited, and quality and safety data are lacking.

How is SR9009 measured?

Liquid chromatography-tandem mass spectrometry is a common approach. It can detect the parent compound and its metabolites in biological matrices.

Network